

# Neisseria meningitidis Infections - Pipeline Review, H2 2020

<https://marketpublishers.com/r/NFA69896059EN.html>

Date: October 2020

Pages: 95

Price: US\$ 2,000.00 (Single User License)

ID: NFA69896059EN

## Abstracts

Neisseria meningitidis Infections - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2020, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by

Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 5, 2, 1, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase 0, Preclinical, Discovery and Unknown stages comprises 1, 2, 1, 2, 1 and 1 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route

of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for *Neisseria meningitidis* Infections (Infectious Disease)

## REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for *Neisseria meningitidis* Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding *Neisseria meningitidis* Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Neisseria meningitidis Infections - Overview
- Neisseria meningitidis Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Neisseria meningitidis Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Bioworld Technologies Sdn Bhd
- CanSino Biologics Inc
- Chongqing Zhifei Biological Products Co Ltd
- GlaxoSmithKline Plc
- Hilleman Laboratories Pvt Ltd
- ImmunoBiology Ltd
- Johnson & Johnson
- Lanzhou Institute of Biological Products Co Ltd
- Neoculi Pty Ltd
- Novo Medi Sciences Pvt Ltd
- Omvax Inc
- Pfizer Inc
- ReAlta Life Sciences Inc
- Sanofi
- Wellstat Vaccines LLC
- Neisseria meningitidis Infections - Drug Profiles
- (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis
- (acellular) + tetanus) vaccine - Drug Profile
- Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACYW-135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MenBioVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, B, C] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
meningococcal [serotypes A, C] (bivalent) vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
meningococcal [serotypes C, Y] vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
meningococcal [serotypes C] vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
meningococcal [strain C2135] vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
meningococcal vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
meningococcal vaccine 1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
NCL-195 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Neisseria meningitidis [serotype B] vaccine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

PF-06886992 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RLS-0071 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis Infections - Dormant Projects

Neisseria meningitidis Infections - Discontinued Products

Neisseria meningitidis Infections - Product Development Milestones

Featured News & Press Releases

Sep 17, 2020: Sanofi receives CHMP positive opinion for MenQuadfi intended for prophylaxis against invasive meningococcal disease

Jun 22, 2020: Pfizer announces start of Phase 3 Clinical Trial of MenABCWY

May 29, 2020: The European Medicines Agency has finalised its assessment of an application to extend the use of Trumenba for the prevention of invasive meningococcal disease

Aug 29, 2019: \$440 million funding boost for vital health and medical research for all stages of life

Nov 28, 2018: NIHR supports world-first trial of new nose drop to fight meningitis

Jun 27, 2018: European approval for lower dose of GSK's Meningitis vaccine

Jun 18, 2018: New way to determine protection of Men B vaccine against different strains

Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years

Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Canada

Feb 07, 2018: GSK's meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age

Dec 13, 2017: Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Data Published In New England Journal Of Medicine Demonstrate The Vaccine's Immunogenicity

Nov 22, 2017: Meningococcal Vaccine Antigens expressed by 91 Percent of Tested



## Bacterial Strains

Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease

Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection

May 30, 2017: European Commission Approves Pfizer's Trumenba To Help Prevent Meningococcal Group B Disease In Adolescents And Adults

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Neisseria meningitidis Infections, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020

Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, H2 2020

Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, H2 2020

Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020

Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H2 2020

Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H2 2020

Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H2 2020

Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, H2 2020

Neisseria meningitidis Infections - Pipeline by Lanzhou Institute of Biological Products Co Ltd, H2 2020

Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, H2 2020

Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, H2 2020

Neisseria meningitidis Infections - Pipeline by Omvax Inc, H2 2020

Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H2 2020

Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, H2 2020

Neisseria meningitidis Infections - Pipeline by Sanofi, H2 2020

Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H2 2020

Neisseria meningitidis Infections - Dormant Projects, H2 2020

Neisseria meningitidis Infections - Dormant Projects, H2 2020 (Contd..1), H2 2020

Neisseria meningitidis Infections - Dormant Projects, H2 2020 (Contd..2), H2 2020

Neisseria meningitidis Infections - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Neisseria meningitidis Infections, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Targets, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

## I would like to order

Product name: Neisseria meningitidis Infections - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/NFA69896059EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NFA69896059EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970